Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective

Haematologica

Volumn 100, Issue 1, 2015, Pages e18-e20

  Andritsos, Leslie A ^a   Dunavin, Neil ^b   Lozanski, Gerard ^a   Jones, Jeffrey A ^a   Blachly, James S ^a   Lucas, David M ^a   Byrd, John C ^a   Kraut, Eric ^a   Grever, Michael R ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Hairy cell leukemia; Pentostatin

Indexed keywords

ANTIBIOTIC AGENT; CLADRIBINE; FILGRASTIM; PENTOSTATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; APPENDICITIS; BLEEDING; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DRUG DOSE ESCALATION; FEMALE; FLOW CYTOMETRY; HAIRY CELL LEUKEMIA; HUMAN; INFECTION; LETTER; LUNG EMBOLISM; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SINUSITIS; TOOTH ABSCESS; TREATMENT RESPONSE; CANCER STAGING; COMPLICATION; DISEASE MANAGEMENT; DOSE RESPONSE; FOLLOW UP; HEMORRHAGE; LEUKEMIA, HAIRY CELL; PATHOLOGY; PROGNOSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INFECTION; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; PENTOSTATIN; PROGNOSIS; REMISSION INDUCTION;

EID: 84920176103     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.113290     Document Type: Letter

References (15)

1. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13(7):609-30.
2. Grever MR, Lozanski G. Modern strategies for hairy cell leukemia. J Clin Oncol. 2011;29(5):583-90.
3. Grever MR. How I treat hairy cell leukemia. Blood. 2010;115 (1):21-8.
4. Dearden CE, Else M, Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma. 2011;52 Suppl 2:21-4.
5. Grever MR, Zinzani PL. Long-term follow-up studies in hairy cell leukemia. Leuk Lymphoma. 2009;50 Suppl 1:23-6.
6. Zinzani PL, Pellegrini C, Stefoni V, Derenzini E, Gandolfi L, Broccoli A, et al. Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. Cancer. 2010;116(20):4788-92.
7. Damaj G, Kuhnowski F, Marolleau JP, Bauters F, Leleu X, Yakoub- Agha I. Risk factors for severe infection in patients with hairy cell leukemia: a long-term study of 73 patients. Eur J Haematol. 2009; 83(3):246-50.
8. Kraut E. Infectious complications in hairy cell leukemia. Leuk Lymphoma. 2011;52 Suppl 2:50-2.
9. Tadmor T. Purine analog toxicity in patients with hairy cell leukemia. Leuk Lymphoma. 2011;52 Suppl 2:38-42.
10. Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 1995;13(4):974-82.
11. Kraut E., Bouroncle BA, Grever MR. Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol. 1989;7(2):168-72.
12. Kraut E., Neff JC, Bouroncle BA, Gochnour D, Grever MR. Immunosuppressive effects of pentostatin. J Clin Oncol. 1990; 8(5):848-55.
13. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood. 1998;92(6):1918-26.
14. Robak T, Jamroziak K, Gora-Tybor J, Blonski JZ, Kasznicki M, Dwilewicz-Trojaczek J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood. 2007;109(9):3672-5.
15. Zenhausern R, Schmitz SF, Solenthaler M, Heim D, Meyer-Monard S, Hess U, et al. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leuk Lymphoma. 2009; 50(9):1501-11.